company background image
RNA logo

Avidity Biosciences NasdaqGM:RNA Stock Report

Last Price

US$37.93

Market Cap

US$4.6b

7D

-12.5%

1Y

378.3%

Updated

04 Dec, 2024

Data

Company Financials +

Avidity Biosciences, Inc.

NasdaqGM:RNA Stock Report

Market Cap: US$4.6b

Avidity Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Avidity Biosciences
Historical stock prices
Current Share PriceUS$37.93
52 Week HighUS$56.00
52 Week LowUS$6.79
Beta0.89
11 Month Change-15.37%
3 Month Change-6.94%
1 Year Change378.31%
33 Year Change46.56%
5 Year Changen/a
Change since IPO33.09%

Recent News & Updates

Recent updates

Avidity Biosciences: Intriguing Oligonucleotide Program To Monitor Over Longer Term

Oct 02

Avidity: Moving RNA Development Landscape Forward Towards Rare Muscle Disorders

Aug 16

Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Aug 14
Avidity Biosciences, Inc. (NASDAQ:RNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$66.67

Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Aug 11
Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)

Avidity Biosciences: Muscular Dystrophy Breakthrough Propels To A 'Buy' Upgrade

Jun 14

Avidity Biosciences: Strong Buy With Promising RNA Therapeutics Pipeline

May 19

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Mar 01
Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

Feb 29

Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Nov 04
Is Avidity Biosciences (NASDAQ:RNA) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Apr 08
Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Nov 17
Here's Why We're Not Too Worried About Avidity Biosciences' (NASDAQ:RNA) Cash Burn Situation

Avidity slips 20% as FDA places lead asset on partial clinical hold

Sep 27

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Jul 29
We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Avidity stock rises amid Chardan starting coverage with Buy

Jul 20

Avidity, Dyn gain as Raymond James turns bullish on targeted oligonucleotides

Jul 12

We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Mar 26
We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely

Avidity Biosciences: Risks And Potential

Dec 09

We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Nov 30
We Think Avidity Biosciences (NASDAQ:RNA) Can Afford To Drive Business Growth

Shareholder Returns

RNAUS BiotechsUS Market
7D-12.5%-0.8%0.4%
1Y378.3%12.9%32.3%

Return vs Industry: RNA exceeded the US Biotechs industry which returned 12.9% over the past year.

Return vs Market: RNA exceeded the US Market which returned 32.3% over the past year.

Price Volatility

Is RNA's price volatile compared to industry and market?
RNA volatility
RNA Average Weekly Movement9.5%
Biotechs Industry Average Movement10.0%
Market Average Movement6.3%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Stable Share Price: RNA has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: RNA's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012253Sarah Boycewww.aviditybiosciences.com

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company’s lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.

Avidity Biosciences, Inc. Fundamentals Summary

How do Avidity Biosciences's earnings and revenue compare to its market cap?
RNA fundamental statistics
Market capUS$4.59b
Earnings (TTM)-US$280.49m
Revenue (TTM)US$10.12m

447.3x

P/S Ratio

-16.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RNA income statement (TTM)
RevenueUS$10.12m
Cost of RevenueUS$260.79m
Gross Profit-US$250.67m
Other ExpensesUS$29.82m
Earnings-US$280.49m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.35
Gross Margin-2,477.69%
Net Profit Margin-2,772.44%
Debt/Equity Ratio0%

How did RNA perform over the long term?

See historical performance and comparison